Join the 'Pulmonary Thromboembolism' group to help and get support from people like you.
Pulmonary Thromboembolism News
Posted 16 Sep 2014 by Drugs.com
TUESDAY, Sept. 16, 2014 – Almost all the various treatment options for blood clots that form in veins are equally safe and effective, new research shows. In exploring the safety and effectiveness of treatments for such blood clots as deep vein thrombosis or pulmonary embolism (blood clot in a lung), Canadian researchers analyzed outcomes associated with eight blood-thinning options, including unfractionated heparin, low-molecular-weight heparin (LMWH) and fondaparinux in combination with vitamin K antagonists. The investigators also examined LMWH with dabigatran (Pradaxa), edoxaban, rivaroxaban (Xarelto), apixaban (Eliquis), as well as LMWH alone. After examining nearly 50 randomized studies, the researchers found that unfractionated heparin combined with vitamin K antagonist was associated with a higher percentage of recurrent blood clots over the course of three months than the ... Read more
Related support groups: Xarelto, Deep Vein Thrombosis (DVT), Pradaxa, Pulmonary Embolism, Eliquis, Deep Vein Thrombosis, Heparin, Rivaroxaban, Apixaban, Thrombotic/Thromboembolic Disorder, Arixtra, Hep-Pak, Dabigatran, Fondaparinux, Venous Thromboembolism, Pulmonary Thromboembolism, Heparin Sodium, Arixtra 10 mg/dose, Arixtra 7.5 mg/dose, Hep-Pak CVC